Myelodysplastic syndromes (MDS) are rare blood cancers, affecting roughly 4 to 5 people per 100,000 in the United States each year. That translates to more than 10,000 new cases annually, with an estimated 60,000 or more Americans living with the condition at any given time. By the federal definition of a rare disease (fewer than 200,000 affected people nationwide), MDS clearly qualifies.
But “rare” doesn’t tell the whole story. MDS is dramatically more common in older adults, more frequent in men, and often underdiagnosed. For certain populations, the numbers look very different than the overall average suggests.
Age Changes the Numbers Drastically
MDS is almost unheard of in young people but becomes increasingly common with age. National cancer registry data from SEER breaks this down clearly:
- Under 40: 0.2 per 100,000 per year
- Ages 40 to 49: 0.8 per 100,000
- Ages 70 to 79: 30.4 per 100,000
- Ages 80 and older: 59.1 per 100,000
That means someone over 80 is roughly 300 times more likely to be diagnosed than someone under 40. When researchers looked specifically at Medicare data for people 65 and older, the incidence climbed as high as 75 per 100,000, a figure that puts MDS squarely among the more common blood cancers in the elderly. The overall “rare” label, while technically accurate, obscures how frequently hematologists encounter MDS in older patients.
Men Are Diagnosed More Often Than Women
MDS shows a consistent male skew. In large datasets, about 55% of cases occur in men and 45% in women. The reasons aren’t entirely clear, but several biological factors likely contribute. Men tend to have faster age-related changes to their DNA, including shorter protective caps on chromosomes (telomeres) and more rapid shifts in the chemical markers that regulate gene activity. Men also carry a higher burden of cardiovascular, lung, and liver disease at the time of diagnosis, which complicates both detection and treatment.
There’s also a treatment angle: men produce higher levels of an enzyme that breaks down two of the most commonly used MDS medications, potentially making those drugs less effective. This doesn’t explain why men get MDS more often, but it does mean the disease tends to be harder to manage once diagnosed.
What MDS Actually Is
MDS is a group of cancers in which the bone marrow produces abnormal, poorly functioning blood cells. The defining feature is dysplasia, meaning the blood cells look and behave abnormally under a microscope. Doctors distinguish MDS from acute myeloid leukemia (AML) based on the percentage of immature cells (blasts) in the bone marrow. Below 20% blasts is classified as MDS; at 20% or above, the diagnosis shifts to AML.
There are several subtypes of MDS, classified by which blood cell lines are affected, how many blasts are present, and which genetic mutations are driving the disease. Some forms involve excess blasts and carry a higher risk of transforming into AML. Others are defined by specific genetic changes, such as a deletion on chromosome 5 or mutations in genes that regulate how cells read their DNA. The subtype matters enormously for prognosis.
About 10 to 20 Percent of Cases Are Treatment-Related
Most MDS cases arise without an obvious external cause. But an estimated 10% to 20% of all MDS and AML cases are classified as therapy-related, meaning they develop as a late consequence of chemotherapy or radiation treatment for a previous cancer. This form of MDS, sometimes called secondary MDS, tends to appear years after the original cancer treatment and generally carries a worse prognosis than MDS that develops on its own.
Survival Varies Widely by Risk Category
Because MDS encompasses such a range of disease severity, survival statistics span from over a decade to under a year. A molecular scoring system now used widely in clinical practice sorts patients into risk groups based on their specific genetic mutations, blood counts, and blast percentages. The median survival for each group gives a sense of this range:
- Very low risk: 10.6 years
- Low risk: 6 years
- Moderate low risk: 4.6 years
- Moderate high risk: 2.8 years
- High risk: 1.7 years
- Very high risk: 1 year
These are medians, so half of patients in each group live longer and half shorter. For someone in the very low risk category, MDS may be a chronic condition managed over many years. For someone in the very high risk category, the disease behaves more like an aggressive leukemia.
Why MDS Is Likely Undercounted
MDS wasn’t even reportable to national cancer registries in the United States until 2001. Before that, cases simply weren’t tracked. Even after reporting began, incidence rates climbed steadily from 3.6 per 100,000 in 2001 to between 4.1 and 4.6 per 100,000 by 2003 to 2008. That increase almost certainly reflects better detection and more complete reporting rather than a true surge in the disease.
MDS also requires a bone marrow biopsy to diagnose, and many elderly patients with mild symptoms (fatigue, low blood counts) may never undergo one. Some cases are likely managed as unexplained anemia without ever receiving a formal MDS diagnosis. The true incidence, particularly among the very old, is probably higher than official statistics capture.